Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

NCT06434363 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Autoimmune Disorders
Systemic Sclerosis
Systemic Lupus Erythematosus
Lupus
Lupus Nephritis

Interventions

DRUG: Tafasitamab
DRUG: Fludarabine phosphate
DRUG: Cyclophosphamide
DRUG: Tafasitamab and NK cells

Sponsor

M.D. Anderson Cancer Center